Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis: prospective study

Most patients with progressive systemic sclerosis (PSS) exhibit lung involvement. However, the natural history of lung disease in PSS remains poorly defined. To evaluate lung function over time in PSS, a battery of lung function tests were prospectively performed serially between 1973 and 1982 in 61...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of medicine 1987-07, Vol.83 (1), p.83-92
Hauptverfasser: GREENWALD, G. I, TASHKIN, D. P, GONG, H, SIMMONS, M, DUANN, S, FURST, D. E, CLEMENTS, P
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 92
container_issue 1
container_start_page 83
container_title The American journal of medicine
container_volume 83
creator GREENWALD, G. I
TASHKIN, D. P
GONG, H
SIMMONS, M
DUANN, S
FURST, D. E
CLEMENTS, P
description Most patients with progressive systemic sclerosis (PSS) exhibit lung involvement. However, the natural history of lung disease in PSS remains poorly defined. To evaluate lung function over time in PSS, a battery of lung function tests were prospectively performed serially between 1973 and 1982 in 61 patients with PSS. Functional indexes of restriction (vital capacity and total lung capacity) and diffusion impairment (diffusing capacity) showed greater-than-expected annual rates of change. Male subjects showed a trend toward faster declines in forced vital capacity, forced expired volume in one second, total lung capacity, and functional residual capacity and a more rapid increase in static recoil pressure at 90 percent of total lung capacity than did female subjects. Nonsmokers had greater rates of decline in total lung capacity and static lung compliance (but not in forced vital capacity or diffusing capacity) and a greater rate of increase in static recoil pressure than did current and former smokers. Level of lung function at initial study visit, age, race, and chlorambucil therapy had no significant effect on the annual rates of change in lung function, whereas longer duration of disease prior to study entry was associated with a slower annual decrease in lung volumes. Between the first and last visits (mean interval 3.1 years, maximum nine years), the frequency of abnormality in pulmonary function test results showed significant change only in the diffusing capacity (60 percent increasing to 82 percent) and static lung compliance (40 percent increasing to 54 percent), whereas the frequency of respiratory symptoms showed little change. These findings indicate an overall indolent progression of PSS-related lung disease, with substantial individual variability.
doi_str_mv 10.1016/0002-9343(87)90501-8
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_77609008</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77609008</sourcerecordid><originalsourceid>FETCH-LOGICAL-p235t-80d0fb5d08a68ae809b8ad589bcf3404ccbf93805d6194c7105cdf02c50bbd93</originalsourceid><addsrcrecordid>eNo9kE1LxDAQhoMo67r6DxRyENFDddI0beJNFr9gwcveS5qkNdKmtdMK_fd2ddnTMPM8vDMMIZcM7hmw9AEA4kjxhN_K7E6BABbJI7JkQogoY2l8TJYH5ZScIX7NLSiRLsiCcwAeZ0uCmzZUfhitD7qm5lOHyiH1gdZjqGg5BjP4NlAdLO0ddr7XQ9tPFKemG9rmz-z6tpoZ-h83z3FwjTcUTe36Fj0-7jh2bs7Z8XnTdE5OSl2ju9jXFdm-PG_Xb9Hm4_V9_bSJupiLIZJgoSyEBalTqZ0EVUhthVSFKXkCiTFFqbgEYVOmEpMxEMaWEBsBRWEVX5Gb_9j5gO_R4ZA3Ho2rax1cO2KeZSkoADmLV3txLBpn8673je6nfP-kmV_vuUaj67LXwXg8aDJWsWSK_wJcEHoQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77609008</pqid></control><display><type>article</type><title>Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis: prospective study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>GREENWALD, G. I ; TASHKIN, D. P ; GONG, H ; SIMMONS, M ; DUANN, S ; FURST, D. E ; CLEMENTS, P</creator><creatorcontrib>GREENWALD, G. I ; TASHKIN, D. P ; GONG, H ; SIMMONS, M ; DUANN, S ; FURST, D. E ; CLEMENTS, P</creatorcontrib><description>Most patients with progressive systemic sclerosis (PSS) exhibit lung involvement. However, the natural history of lung disease in PSS remains poorly defined. To evaluate lung function over time in PSS, a battery of lung function tests were prospectively performed serially between 1973 and 1982 in 61 patients with PSS. Functional indexes of restriction (vital capacity and total lung capacity) and diffusion impairment (diffusing capacity) showed greater-than-expected annual rates of change. Male subjects showed a trend toward faster declines in forced vital capacity, forced expired volume in one second, total lung capacity, and functional residual capacity and a more rapid increase in static recoil pressure at 90 percent of total lung capacity than did female subjects. Nonsmokers had greater rates of decline in total lung capacity and static lung compliance (but not in forced vital capacity or diffusing capacity) and a greater rate of increase in static recoil pressure than did current and former smokers. Level of lung function at initial study visit, age, race, and chlorambucil therapy had no significant effect on the annual rates of change in lung function, whereas longer duration of disease prior to study entry was associated with a slower annual decrease in lung volumes. Between the first and last visits (mean interval 3.1 years, maximum nine years), the frequency of abnormality in pulmonary function test results showed significant change only in the diffusing capacity (60 percent increasing to 82 percent) and static lung compliance (40 percent increasing to 54 percent), whereas the frequency of respiratory symptoms showed little change. These findings indicate an overall indolent progression of PSS-related lung disease, with substantial individual variability.</description><identifier>ISSN: 0002-9343</identifier><identifier>EISSN: 1555-7162</identifier><identifier>DOI: 10.1016/0002-9343(87)90501-8</identifier><identifier>PMID: 3300327</identifier><identifier>CODEN: AJMEAZ</identifier><language>eng</language><publisher>New York, NY: Elsevier</publisher><subject>Adult ; Biological and medical sciences ; Chlorambucil - therapeutic use ; Clinical Trials as Topic ; Double-Blind Method ; Female ; Humans ; Lung - physiopathology ; Male ; Medical sciences ; Middle Aged ; Prospective Studies ; Random Allocation ; Respiratory Function Tests ; Respiratory Tract Diseases - etiology ; Respiratory Tract Diseases - physiopathology ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis ; Scleroderma, Systemic - complications ; Scleroderma, Systemic - drug therapy ; Scleroderma, Systemic - physiopathology ; Smoking ; Time Factors</subject><ispartof>The American journal of medicine, 1987-07, Vol.83 (1), p.83-92</ispartof><rights>1987 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=8292819$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3300327$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GREENWALD, G. I</creatorcontrib><creatorcontrib>TASHKIN, D. P</creatorcontrib><creatorcontrib>GONG, H</creatorcontrib><creatorcontrib>SIMMONS, M</creatorcontrib><creatorcontrib>DUANN, S</creatorcontrib><creatorcontrib>FURST, D. E</creatorcontrib><creatorcontrib>CLEMENTS, P</creatorcontrib><title>Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis: prospective study</title><title>The American journal of medicine</title><addtitle>Am J Med</addtitle><description>Most patients with progressive systemic sclerosis (PSS) exhibit lung involvement. However, the natural history of lung disease in PSS remains poorly defined. To evaluate lung function over time in PSS, a battery of lung function tests were prospectively performed serially between 1973 and 1982 in 61 patients with PSS. Functional indexes of restriction (vital capacity and total lung capacity) and diffusion impairment (diffusing capacity) showed greater-than-expected annual rates of change. Male subjects showed a trend toward faster declines in forced vital capacity, forced expired volume in one second, total lung capacity, and functional residual capacity and a more rapid increase in static recoil pressure at 90 percent of total lung capacity than did female subjects. Nonsmokers had greater rates of decline in total lung capacity and static lung compliance (but not in forced vital capacity or diffusing capacity) and a greater rate of increase in static recoil pressure than did current and former smokers. Level of lung function at initial study visit, age, race, and chlorambucil therapy had no significant effect on the annual rates of change in lung function, whereas longer duration of disease prior to study entry was associated with a slower annual decrease in lung volumes. Between the first and last visits (mean interval 3.1 years, maximum nine years), the frequency of abnormality in pulmonary function test results showed significant change only in the diffusing capacity (60 percent increasing to 82 percent) and static lung compliance (40 percent increasing to 54 percent), whereas the frequency of respiratory symptoms showed little change. These findings indicate an overall indolent progression of PSS-related lung disease, with substantial individual variability.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Chlorambucil - therapeutic use</subject><subject>Clinical Trials as Topic</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Lung - physiopathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Prospective Studies</subject><subject>Random Allocation</subject><subject>Respiratory Function Tests</subject><subject>Respiratory Tract Diseases - etiology</subject><subject>Respiratory Tract Diseases - physiopathology</subject><subject>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><subject>Scleroderma, Systemic - complications</subject><subject>Scleroderma, Systemic - drug therapy</subject><subject>Scleroderma, Systemic - physiopathology</subject><subject>Smoking</subject><subject>Time Factors</subject><issn>0002-9343</issn><issn>1555-7162</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kE1LxDAQhoMo67r6DxRyENFDddI0beJNFr9gwcveS5qkNdKmtdMK_fd2ddnTMPM8vDMMIZcM7hmw9AEA4kjxhN_K7E6BABbJI7JkQogoY2l8TJYH5ZScIX7NLSiRLsiCcwAeZ0uCmzZUfhitD7qm5lOHyiH1gdZjqGg5BjP4NlAdLO0ddr7XQ9tPFKemG9rmz-z6tpoZ-h83z3FwjTcUTe36Fj0-7jh2bs7Z8XnTdE5OSl2ju9jXFdm-PG_Xb9Hm4_V9_bSJupiLIZJgoSyEBalTqZ0EVUhthVSFKXkCiTFFqbgEYVOmEpMxEMaWEBsBRWEVX5Gb_9j5gO_R4ZA3Ho2rax1cO2KeZSkoADmLV3txLBpn8673je6nfP-kmV_vuUaj67LXwXg8aDJWsWSK_wJcEHoQ</recordid><startdate>19870701</startdate><enddate>19870701</enddate><creator>GREENWALD, G. I</creator><creator>TASHKIN, D. P</creator><creator>GONG, H</creator><creator>SIMMONS, M</creator><creator>DUANN, S</creator><creator>FURST, D. E</creator><creator>CLEMENTS, P</creator><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19870701</creationdate><title>Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis: prospective study</title><author>GREENWALD, G. I ; TASHKIN, D. P ; GONG, H ; SIMMONS, M ; DUANN, S ; FURST, D. E ; CLEMENTS, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p235t-80d0fb5d08a68ae809b8ad589bcf3404ccbf93805d6194c7105cdf02c50bbd93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Chlorambucil - therapeutic use</topic><topic>Clinical Trials as Topic</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Lung - physiopathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Prospective Studies</topic><topic>Random Allocation</topic><topic>Respiratory Function Tests</topic><topic>Respiratory Tract Diseases - etiology</topic><topic>Respiratory Tract Diseases - physiopathology</topic><topic>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</topic><topic>Scleroderma, Systemic - complications</topic><topic>Scleroderma, Systemic - drug therapy</topic><topic>Scleroderma, Systemic - physiopathology</topic><topic>Smoking</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GREENWALD, G. I</creatorcontrib><creatorcontrib>TASHKIN, D. P</creatorcontrib><creatorcontrib>GONG, H</creatorcontrib><creatorcontrib>SIMMONS, M</creatorcontrib><creatorcontrib>DUANN, S</creatorcontrib><creatorcontrib>FURST, D. E</creatorcontrib><creatorcontrib>CLEMENTS, P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GREENWALD, G. I</au><au>TASHKIN, D. P</au><au>GONG, H</au><au>SIMMONS, M</au><au>DUANN, S</au><au>FURST, D. E</au><au>CLEMENTS, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis: prospective study</atitle><jtitle>The American journal of medicine</jtitle><addtitle>Am J Med</addtitle><date>1987-07-01</date><risdate>1987</risdate><volume>83</volume><issue>1</issue><spage>83</spage><epage>92</epage><pages>83-92</pages><issn>0002-9343</issn><eissn>1555-7162</eissn><coden>AJMEAZ</coden><abstract>Most patients with progressive systemic sclerosis (PSS) exhibit lung involvement. However, the natural history of lung disease in PSS remains poorly defined. To evaluate lung function over time in PSS, a battery of lung function tests were prospectively performed serially between 1973 and 1982 in 61 patients with PSS. Functional indexes of restriction (vital capacity and total lung capacity) and diffusion impairment (diffusing capacity) showed greater-than-expected annual rates of change. Male subjects showed a trend toward faster declines in forced vital capacity, forced expired volume in one second, total lung capacity, and functional residual capacity and a more rapid increase in static recoil pressure at 90 percent of total lung capacity than did female subjects. Nonsmokers had greater rates of decline in total lung capacity and static lung compliance (but not in forced vital capacity or diffusing capacity) and a greater rate of increase in static recoil pressure than did current and former smokers. Level of lung function at initial study visit, age, race, and chlorambucil therapy had no significant effect on the annual rates of change in lung function, whereas longer duration of disease prior to study entry was associated with a slower annual decrease in lung volumes. Between the first and last visits (mean interval 3.1 years, maximum nine years), the frequency of abnormality in pulmonary function test results showed significant change only in the diffusing capacity (60 percent increasing to 82 percent) and static lung compliance (40 percent increasing to 54 percent), whereas the frequency of respiratory symptoms showed little change. These findings indicate an overall indolent progression of PSS-related lung disease, with substantial individual variability.</abstract><cop>New York, NY</cop><pub>Elsevier</pub><pmid>3300327</pmid><doi>10.1016/0002-9343(87)90501-8</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0002-9343
ispartof The American journal of medicine, 1987-07, Vol.83 (1), p.83-92
issn 0002-9343
1555-7162
language eng
recordid cdi_proquest_miscellaneous_77609008
source MEDLINE; Elsevier ScienceDirect Journals
subjects Adult
Biological and medical sciences
Chlorambucil - therapeutic use
Clinical Trials as Topic
Double-Blind Method
Female
Humans
Lung - physiopathology
Male
Medical sciences
Middle Aged
Prospective Studies
Random Allocation
Respiratory Function Tests
Respiratory Tract Diseases - etiology
Respiratory Tract Diseases - physiopathology
Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
Scleroderma, Systemic - complications
Scleroderma, Systemic - drug therapy
Scleroderma, Systemic - physiopathology
Smoking
Time Factors
title Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis: prospective study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T23%3A28%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Longitudinal%20changes%20in%20lung%20function%20and%20respiratory%20symptoms%20in%20progressive%20systemic%20sclerosis:%20prospective%20study&rft.jtitle=The%20American%20journal%20of%20medicine&rft.au=GREENWALD,%20G.%20I&rft.date=1987-07-01&rft.volume=83&rft.issue=1&rft.spage=83&rft.epage=92&rft.pages=83-92&rft.issn=0002-9343&rft.eissn=1555-7162&rft.coden=AJMEAZ&rft_id=info:doi/10.1016/0002-9343(87)90501-8&rft_dat=%3Cproquest_pubme%3E77609008%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77609008&rft_id=info:pmid/3300327&rfr_iscdi=true